Royalty Pharma reports Q2 results; raises FY outlook

2 hours ago 1

Royalty Pharma press release (NASDAQ:RPRX): Q2 Revenue of $579M (+7.8% Y/Y) misses by $114.74M.
As of June 30, 2025, Royalty Pharma had cash and cash equivalents of $632 million and total debt with principal value of $8.2 billion.
Portfolio Receipts growth

Recommended For You